--- title: "Institutional investors in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) see US$21m decrease in market cap last week, although long-term gains have benefitted them." description: "Institutional investors in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) experienced a US$21 million decrease in market cap last week, with their holdings dropping 12% in value. Despite this, they have see" type: "news" locale: "en" url: "https://longbridge.com/en/news/234648269.md" published_at: "2025-04-05T20:11:26.000Z" --- # Institutional investors in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) see US$21m decrease in market cap last week, although long-term gains have benefitted them. > Institutional investors in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) experienced a US$21 million decrease in market cap last week, with their holdings dropping 12% in value. Despite this, they have seen an 18% return over the past year. Institutions hold about 46% of the shares, indicating significant influence on stock performance. Hedge funds own 28%, with BML Capital Management being the largest shareholder. Insider ownership is relatively low at 1.4%, while the general public holds 15%. The concentration of ownership suggests potential volatility in stock price due to institutional trading decisions. ### Key Insights - Given the large stake in the stock by institutions, Aclaris Therapeutics' stock price might be vulnerable to their trading decisions - A total of 8 investors have a majority stake in the company with 50% ownership - Ownership research along with analyst forecasts data help provide a good understanding of opportunities in a stock This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. If you want to know who really controls Aclaris Therapeutics, Inc. (NASDAQ:ACRS), then you'll have to look at the makeup of its share registry. The group holding the most number of shares in the company, around 46% to be precise, is institutions. Put another way, the group faces the maximum upside potential (or downside risk). No shareholder likes losing money on their investments, especially institutional investors who saw their holdings drop 12% in value last week. However, the 18% one-year returns may have helped alleviate their overall losses. They should, however, be mindful of further losses in the future. Let's take a closer look to see what the different types of shareholders can tell us about Aclaris Therapeutics. View our latest analysis for Aclaris Therapeutics ## What Does The Institutional Ownership Tell Us About Aclaris Therapeutics? Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing. As you can see, institutional investors have a fair amount of stake in Aclaris Therapeutics. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Aclaris Therapeutics, (below). Of course, keep in mind that there are other factors to consider, too. It looks like hedge funds own 28% of Aclaris Therapeutics shares. That catches my attention because hedge funds sometimes try to influence management, or bring about changes that will create near term value for shareholders. Our data shows that BML Capital Management, LLC is the largest shareholder with 13% of shares outstanding. Meanwhile, the second and third largest shareholders, hold 8.9% and 8.2%, of the shares outstanding, respectively. In addition, we found that Neal Walker, the CEO has 1.4% of the shares allocated to their name. On further inspection, we found that more than half the company's shares are owned by the top 8 shareholders, suggesting that the interests of the larger shareholders are balanced out to an extent by the smaller ones. Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too. ## Insider Ownership Of Aclaris Therapeutics The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it. Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group. Our most recent data indicates that insiders own some shares in Aclaris Therapeutics, Inc.. In their own names, insiders own US$4.3m worth of stock in the US$161m company. It is good to see some investment by insiders, but we usually like to see higher insider holdings. It might be worth checking if those insiders have been buying. ## General Public Ownership The general public-- including retail investors -- own 15% stake in the company, and hence can't easily be ignored. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run. ## Private Equity Ownership With a stake of 8.2%, private equity firms could influence the Aclaris Therapeutics board. Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company. Alternatively, those holders might be exiting the investment after taking it public. ## Next Steps: It's always worth thinking about the different groups who own shares in a company. But to understand Aclaris Therapeutics better, we need to consider many other factors. Like risks, for instance. Every company has them, and we've spotted **3 warning signs for Aclaris Therapeutics** (of which 2 don't sit too well with us!) you should know about. If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future . NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. If you're looking to trade Aclaris Therapeutics, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers. With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account. Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer. Sponsored Content ### Related Stocks - [ACRS.US - Aclaris Therap](https://longbridge.com/en/quote/ACRS.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Aclaris Therapeutics 宣傳其 TSLP 和 ITK 管線，並計劃在 2026 年進行多項臨牀結果發佈 | Aclaris Therapeutics（納斯達克代碼：ACRS）在古根海姆新興前景生物技術峯會上介紹了其生物製劑和口服小分子管線的發展優先事項和里程碑。該公司專注於一個針對 TSLP 的抗體平台和一個以 ITK 為重點的激酶抑制業務，預計 | [Link](https://longbridge.com/en/news/275827675.md) | | Aclaris Therapeutics 擴展其在炎症和免疫學領域的管線策略 | Aclaris Therapeutics 已擴展其炎症和免疫學管線，專注於針對 Th1、Th2 和 Th17 介導疾病的創新療法。更新後的公司戰略包括四個預期的臨牀項目，並強調資本管理和戰略合作伙伴關係。最新的分析師評級為 ACRS 股票持 | [Link](https://longbridge.com/en/news/272270423.md) | | Aclaris Therapeutics 公佈 ATI-052 在 1a 期試驗中的積極數據 | Aclaris Therapeutics, Inc. (ACRS) 報告了 ATI-052 的 1a 期臨牀試驗的積極中期結果，表明該藥物耐受性良好，安全性良好。該藥物顯示出潛在的最佳藥代動力學特徵，有效半衰期至少為 26 天。Aclari | [Link](https://longbridge.com/en/news/271653199.md) | | Ascelia Pharma AB 報告 2025 年全年運營結果為-74.4 百萬瑞典克朗，每股收益為-0.67 瑞典克朗，流動資產為 49.9 百萬瑞典克朗 | Ascelia Pharma AB 發佈了 2025 財年的財務結果，顯示營業虧損為 7400 萬瑞典克朗，每股收益為-0.67 瑞典克朗。2025 年第四季度的營業虧損為 1580 萬瑞典克朗。公司擁有流動資產總計 4990 萬瑞典克朗。 | [Link](https://longbridge.com/en/news/274926047.md) | | Aclaris Therapeutics 將在主要醫療保健會議上發表演講 | Aclaris Therapeutics Inc. 將參加 2026 年 2 月的兩場醫療健康會議。首席執行官 Neal Walker 博士和高級領導將於 2 月 12 日在古根海姆新興前景：生物技術峯會上參與爐邊談話，主席 Hugh Da | [Link](https://longbridge.com/en/news/274807454.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.